DNA icon

Alzheimer's Disease, Familial, Panel

Summary and Pricing

Test Method

Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
Test Code Test Copy Genes Gene CPT Codes Copy CPT Codes
APP 81406,81479
PSEN1 81405,81479
PSEN2 81406,81479
Test Code Test Copy Genes Panel CPT Code Gene CPT Codes Copy CPT Code Base Price
3409Genes x (3)81479 81405(x1), 81406(x2), 81479(x3) $990 Order Options and Pricing

Pricing Comments

Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Li Fan, MD, PhD, FCCMG, FACMG

Clinical Features and Genetics of Alzheimer's Disease

Clinical Features

Familial Alzheimer's disease is a neurodegenerative disorder characterized by onset of dementia at a relatively young age. Dementia initially presents in familial Alzheimer's disease patients as short term memory problems or disorientation between 30 and 60 years of age. Cognitive decline is observed over the next 10-20 years with apraxia, progressive memory loss and impaired spatial skills being common presentations (Wallon et al. 2012). Motor disturbances such as cerebellar ataxia and spastic paraparesis are also observed in a subset of patients. The key neuropathology of familial Alzheimer's disease includes: amyloid plaques, neurofibrillary tangles, neuronal loss and brain atrophy (Wu et al. 2012). An important feature of the familial Alzheimer's disease diagnosis is that an individual has at least one affected family member.

Patients with familial Alzheimer's disease caused by PSEN2 pathogenic variants typically show a later age of onset in the 50s or 60s as compared to onset in the 30s or 40s as seen in familial Alzheimer's disease caused by APP or PSEN1 variants (Jayadev et al. 2010). In addition, PSEN2-related familial Alzheimer's disease patients have a higher frequency of behavioral and psychotic symptoms of dementia, such as hallucinations or delusions (Canevelli et al. 2014).


Familial Alzheimer's disease is inherited in an autosomal dominant manner and can be caused by pathogenic variants in the APP, PSEN1 and PSEN2 genes.

The reported APP pathogenic variants are missense, frameshift and small deletion variants mainly contained within exons 16 and 17 of the APP gene. These variants disrupt processing of APP into mature amyloid-beta protein (Janssen et al. 2003; Mullan et al. 1992; Tomiyama et al. 2008). Large duplications and large deletion encompassing the entire APP gene have also been identified in familial Alzheimer's disease patients (McNaughton et al. 2012). A rare recessive pathogenic variant in the APP gene was reported to cause familial Alzheimer's disease (Di Fede et al. 2009). APP encodes amyloid-beta precursor protein (APP). APP is post-translationally processed into two amyloid-beta isoforms: AB40 and AB42. The gamma-secretase complex that processes APP contains the proteins PSEN1 and PSEN2, which play a role in pathogenesis of familial Alzheimer's disease (Sua'rez-Calvet et al. 2014).

Most causative PSEN1 variants are missense variants distributed throughout the gene, though frameshifts, splice site variants and large deletions in PSEN1 have also been identified in familial Alzheimer's disease patients (Rogaeva et al. 2001; Janssen et al. 2003). PSEN1 encodes the presenilin-1 (PS1) protein. PS1 is the catalytic subunit of the gamma-secretase complex which cleaves the Alzheimer's-associated alpha-beta precursor protein (APP). PSEN1 variants are believed to act in a dominant negative manner to interfere with wildtype PS1 activity and to cause Familial Alzheimer's disease via impaired APP processing by gamma-secretase (Nornes et al. 2007; Heilig et al. 2013).

The major causative PSEN2 variants are missense variants. Two variants, N141I and M239V, account for 74% of all PSEN2-related familial Alzheimer's disease cases (Canevelli et al. 2014). No large deletions or duplications have been reported to date. PSEN2 encodes the presenilin-2 (PS2) protein. PS2 is a subunit of the gamma-secretase complex which cleaves the Alzheimer's-associated alpha-beta precursor protein (APP). Although PSEN2 knockout mice do not show amyloid-beta processing defects, pathogenic PSEN2 variants were shown to alter AB40:AB42 ratios in in vitro cell-based assays (Herreman et al. 1999; Walker et al. 2005).

Clinical Sensitivity - Sequencing with CNV PG-Select

Pathogenic variants in PSEN1 gene accounts for 30%-70% of early onset familial Alzheimer's disease while pathogenic variants in the APP gene are identified in ~15% of familial Alzheimer's disease cases. Fewer pathogenic variants are found in PSEN2 gene which account for about 5% of all early onset familial Alzheimer's disease (Marcon et al. 2009; Campion et al 1999; Wallon et al. 2012; Janssen et al. 2003).

In cohorts of autosomal dominant early-onset Alzheimer's disease, the clinical sensitivity of the APP locus duplications can be roughly estimated to be 8% (Rovelet-Lecrux A. et al. 2006). Large deletions in PSEN1 in a large cohort of patients with autosomal dominant early-onset Alzheimer's disease is unavailable in the literature because large deletions have only been reported in individual cases. No large deletions/duplications in PSEN2 have been reported.

Testing Strategy

This panel provides 100% coverage of all coding exons of the genes listed, plus ~10 bases of flanking noncoding DNA. We define coverage as ≥20X NGS reads or Sanger sequencing.

Indications for Test

Candidates for this panel include patients with symptoms suspected for familial Alzheimer's disease.


Official Gene Symbol OMIM ID
APP 104760
PSEN1 104311
PSEN2 600759
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Related Test



  • Campion D. et al. 1999. American Journal of Human Genetics. 65: 664-70. PubMed ID: 10441572
  • Canevelli M. et al. 2014. Neuroscience & Biobehavioral Reviews 42: 170–9. PubMed ID: 24594196
  • Di Fede G. et al. 2009. Science. 323: 1473-7. PubMed ID: 19286555
  • Heilig E.A. et al. 2013. The Journal of Neuroscience. 33: 11606-17. PubMed ID: 23843529
  • Herreman A. et al. 1999. Proceedings of the National Academy of Sciences of the United States of America. 96: 11872-7. PubMed ID: 10518543
  • Janssen J.C. et al. 2003. Neurology. 60: 235-9. PubMed ID: 12552037
  • Jayadev S. et al. 2010. Brain 133: 1143–54. PubMed ID: 23952003
  • Marcon G. et al. 2009. Journal of Alzheimer's Disease. 16: 509-11. PubMed ID: 19276543
  • Mullan M. et al. 1992. Nature Genetics. 1: 345-7. PubMed ID: 1302033
  • Nornes S. et al. 2008. Human Molecular Genetics. 17: 402-12. PubMed ID: 17981814
  • Rogaeva E.A. et al. 2001. Neurology. 57: 621-5. PubMed ID: 11524469
  • Rovelet-Lecrux A. et al. 2006. Nature Genetics. 38: 24-6. PubMed ID: 16369530
  • Suárez-Calvet M. et al. 2014. Journal of Neurochemistry. 128: 330-9. PubMed ID: 24117942
  • Tomiyama T. et al. 2008. Annals of Neurology. 63: 377-87. PubMed ID: 18300294
  • Walker E.S. et al. 2005. Journal of Neurochemistry. 92: 294-301. PubMed ID: 15663477
  • Wallon D. et al. 2012. Journal of Alzheimer's Disease. 30: 847-56. PubMed ID: 22475797
  • Wu L. et al. 2012. The Canadian Journal of Neurological Sciences. 39: 436–445. PubMed ID: 22728850


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

Disease Resources

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard